ABBV · Earnings call · 2026Q3T · Full report

Obesity Portfolio Strategy

AbbVie Inc. · 2026-10-30 · Importance 23 · Surprise 24

AbbVie is interested in expanding its obesity portfolio with differentiated assets that could complement its asset 295, including co-formulations in the incretin class or other mechanisms. Management emphasized improving both efficacy and tolerability, noting that patients continue to start and stop treatments. Combination agents could also support expansion into indications such as hidradenitis suppurativa, where AbbVie is studying amylin approaches.

Key facts

• AbbVie recently initiated a Phase II trial of ABBV-295 in obese patients.
• AbbVie expects interim data from its Phase Ib ABBV-295 study in obese patients around the end of 2026.
• AbbVie reported meaningful weight loss across multiple dosing regimens for ABBV-295 in a Phase I study and a pharmacokinetic profile supporting potential every-other-week or monthly dosing.
• AbbVie remains interested in building obesity assets and is open to differentiated assets that could potentially match its 295, particularly for co-formulation.
• AbbVie is open to obesity co-formulation agents in the incretin class or other classes, with the aim of driving efficacy and tolerability.
• AbbVie said additional combination agents could support entry into other indications where it has leadership in psoriasis and psoriatic arthritis, and potentially HS.
• The mean BMI in AbbVie’s lutikizumab study was almost 34.